PL378902A1 - Doustne postaci użytkowe memantyny - Google Patents

Doustne postaci użytkowe memantyny

Info

Publication number
PL378902A1
PL378902A1 PL378902A PL37890204A PL378902A1 PL 378902 A1 PL378902 A1 PL 378902A1 PL 378902 A PL378902 A PL 378902A PL 37890204 A PL37890204 A PL 37890204A PL 378902 A1 PL378902 A1 PL 378902A1
Authority
PL
Poland
Prior art keywords
dosage forms
oral dosage
memantine oral
memantine
forms
Prior art date
Application number
PL378902A
Other languages
English (en)
Inventor
Bruce A. Firestone
Zanden John J. Vander
Janet K. Cheetham
Richard Kurjan
Teresa H. Kuan
Chin-Ming Chang
J. Abraham M. Espiritu
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of PL378902A1 publication Critical patent/PL378902A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL378902A 2003-06-16 2004-06-10 Doustne postaci użytkowe memantyny PL378902A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47897903P 2003-06-16 2003-06-16

Publications (1)

Publication Number Publication Date
PL378902A1 true PL378902A1 (pl) 2006-05-29

Family

ID=33539133

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378902A PL378902A1 (pl) 2003-06-16 2004-06-10 Doustne postaci użytkowe memantyny

Country Status (16)

Country Link
US (2) US20040254251A1 (pl)
EP (1) EP1631273A1 (pl)
JP (1) JP2006527774A (pl)
KR (1) KR20060033727A (pl)
CN (1) CN1805737A (pl)
AU (1) AU2004249151A1 (pl)
BR (1) BRPI0411451A (pl)
CA (1) CA2529535A1 (pl)
IL (1) IL172233A0 (pl)
MX (1) MXPA05012810A (pl)
NO (1) NO20055880L (pl)
PL (1) PL378902A1 (pl)
RU (1) RU2006101225A (pl)
TW (1) TW200524639A (pl)
WO (1) WO2004112768A1 (pl)
ZA (1) ZA200509379B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7086532B2 (en) * 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
FR2855344A1 (fr) * 2003-05-22 2004-11-26 France Telecom Systeme de gestion de contexte pour un reseau comportant un ensemble heterogene de terminaux
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
CN101389315A (zh) * 2004-06-17 2009-03-18 莫茨药物股份两合公司 美金刚口服剂型即释制剂
EP1827385B1 (en) * 2004-11-23 2013-03-27 Adamas Pharmaceuticals, Inc. Pharmaceutical composition comprising memantine in an extended dosage release form for use in the treatment of dementias
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
AU2005320547B2 (en) 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
CA2604052C (en) 2005-04-06 2014-07-08 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of cns-related conditions
BRPI0608780A2 (pt) * 2005-04-28 2010-11-09 Eisai R&D Man Co Ltd composição contendo fármaco anti-demência
AU2007215005A1 (en) * 2006-02-10 2007-08-23 Janssen Pharmaceutica N.V. Novel tricyclic dihydropyrazines as potassium channel openers
EP2017289A4 (en) * 2006-04-20 2011-07-27 Itoham Foods Inc PHARMACEUTICAL COMPOSITION FOR INFORMATIONAL DISEASE
JP2009542647A (ja) * 2006-07-05 2009-12-03 テバ ファーマシューティカル インダストリーズ リミティド メマンチン医薬組成物
EP1908748A1 (en) * 2006-10-05 2008-04-09 Krka Process for the preparation of memantine and its hydrochloric acid salt form
EP2420235A1 (en) * 2006-10-27 2012-02-22 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
US20100292341A1 (en) * 2007-06-29 2010-11-18 Orchid Chemicals & Pharmaceuticals Limited Quick dissolve compositions of memantine hydrochloride
EP2583669A1 (en) 2007-10-10 2013-04-24 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
WO2009091932A2 (en) * 2008-01-18 2009-07-23 Adamas Pharmaceuticals, Inc. Treatment of mild dementia of the alzheimer's disease type
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
CA2994873A1 (en) 2009-12-02 2011-06-09 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
IN2014MN02029A (pl) * 2012-04-24 2015-08-14 Daiichi Sankyo Companyltd
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
KR20190076711A (ko) 2017-12-22 2019-07-02 한미약품 주식회사 메만틴을 포함하는 속방성 및 서방성을 동시에 가지는 경질캡슐 제제 및 그 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US6849271B2 (en) * 2001-04-27 2005-02-01 Verion, Inc. Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods

Also Published As

Publication number Publication date
RU2006101225A (ru) 2006-06-10
BRPI0411451A (pt) 2006-07-18
US20040254251A1 (en) 2004-12-16
IL172233A0 (en) 2006-04-10
MXPA05012810A (es) 2006-02-13
US20060251717A1 (en) 2006-11-09
NO20055880L (no) 2005-12-28
CN1805737A (zh) 2006-07-19
TW200524639A (en) 2005-08-01
EP1631273A1 (en) 2006-03-08
WO2004112768A1 (en) 2004-12-29
JP2006527774A (ja) 2006-12-07
CA2529535A1 (en) 2004-12-29
AU2004249151A1 (en) 2004-12-29
ZA200509379B (en) 2006-11-29
KR20060033727A (ko) 2006-04-19

Similar Documents

Publication Publication Date Title
IL172233A0 (en) Memantine oral dosage forms
GB0322284D0 (en) Medicament dispenser
GB0217225D0 (en) Medicinal compounds
GB0204719D0 (en) Medicinal compounds
GB0220730D0 (en) Medicinal compounds
GB0324886D0 (en) Medicinal compounds
EP1553925A4 (en) ORAL DOSAGE FORM WITH MODIFIED RELEASE
GB0303396D0 (en) Medicinal compounds
GB0302671D0 (en) Pharmaceutical formulations
AU2003238670A8 (en) Fast disintegrating oral dosage forms
PL377495A1 (pl) Stały lek do stosowania doustnego
IL174342A0 (en) Chronotherapeutic dosage forms
GB0209668D0 (en) Oral devices
IL172824A0 (en) Pharmaceutical formulations
GB0302672D0 (en) Pharmaceutical formulations
GB0328490D0 (en) Medicinal compounds
GB0325383D0 (en) Oral formulations
GB0206505D0 (en) Pharmaceutical combination
GB0316341D0 (en) Pharmaceutical formulations
IL174009A0 (en) Melt-formulated, multi-particulate oral dosage form
ZA200600560B (en) Combined doses
PL373409A1 (pl) Kombinacja farmaceutyczna
HK1089381A (en) Memantine oral dosage forms
GB0315019D0 (en) Dosage form
GB0316335D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)